Yuvidoc-S Tablet is a combination pharmaceutical formulation containing Diclofenac 50mg and Serratiopeptidase 10mg, designed for the management of pain and inflammation associated with various musculoskeletal disorders. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effect by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), leading to a reduction in prostaglandin synthesis, thereby alleviating pain, swelling, and inflammation. Serratiopeptidase, a proteolytic enzyme, complements this action by breaking down inflammatory mediators and facilitating the resolution of edema and fibrosis, which enhances tissue healing. This synergistic combination is particularly effective in conditions such as osteoarthritis, rheumatoid arthritis, post-traumatic swelling, postoperative inflammation, and soft tissue injuries. Yuvidoc-S is indicated for short-term use under medical supervision to minimize potential adverse effects, including gastrointestinal discomfort, ulceration, and hypersensitivity reactions associated with NSAIDs. Caution is advised in patients with a history of peptic ulcers, renal or hepatic impairment, and cardiovascular disease. The tablet should be administered as prescribed, typically with food to reduce gastrointestinal irritation. Overall, Yuvidoc-S Tablet offers a balanced approach to managing inflammatory pain, promoting faster recovery and improved patient comfort.